International Clinical Trial: A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07812090) titled 'A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: BioAge Labs, Inc.

Condition: Diabetic Macular Edema (DME)

Intervention: Drug: Oral BGE-102 Drug: Oral Placebo Matching BGE-102 Drug: Anti-VEGF

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: August 21, 2026

Target Sample Size: 180

Countries of Recruitm...